CN1073415C - 磺酰胺类化合物在制备抗癌药物中的应用 - Google Patents
磺酰胺类化合物在制备抗癌药物中的应用 Download PDFInfo
- Publication number
- CN1073415C CN1073415C CN97108988A CN97108988A CN1073415C CN 1073415 C CN1073415 C CN 1073415C CN 97108988 A CN97108988 A CN 97108988A CN 97108988 A CN97108988 A CN 97108988A CN 1073415 C CN1073415 C CN 1073415C
- Authority
- CN
- China
- Prior art keywords
- anticancer drug
- medicine
- cancers
- ethanol
- dmso
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 230000001093 anti-cancer Effects 0.000 title abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 41
- 229940079593 drug Drugs 0.000 claims abstract description 35
- 239000002904 solvent Substances 0.000 claims abstract description 30
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims abstract description 16
- -1 etc. Substances 0.000 claims abstract description 13
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims abstract description 11
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 claims abstract description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 238000011275 oncology therapy Methods 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 17
- 239000007927 intramuscular injection Substances 0.000 claims description 10
- 238000010255 intramuscular injection Methods 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 8
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000001294 propane Substances 0.000 claims description 2
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 claims 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 claims 1
- 229940125773 compound 10 Drugs 0.000 claims 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims 1
- 229940126701 oral medication Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- 201000011510 cancer Diseases 0.000 abstract description 14
- 238000004519 manufacturing process Methods 0.000 abstract description 10
- 241001465754 Metazoa Species 0.000 abstract description 8
- 239000007788 liquid Substances 0.000 abstract description 7
- 208000014018 liver neoplasm Diseases 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 6
- 229940124530 sulfonamide Drugs 0.000 abstract description 6
- 206010006187 Breast cancer Diseases 0.000 abstract description 5
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 5
- 238000001228 spectrum Methods 0.000 abstract description 4
- 230000001629 suppression Effects 0.000 abstract description 4
- 208000020816 lung neoplasm Diseases 0.000 abstract description 3
- 208000005016 Intestinal Neoplasms Diseases 0.000 abstract description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 2
- 238000001914 filtration Methods 0.000 abstract description 2
- 150000003456 sulfonamides Chemical class 0.000 abstract description 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 8
- 229940041181 antineoplastic drug Drugs 0.000 abstract 8
- 238000001727 in vivo Methods 0.000 abstract 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 abstract 1
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 abstract 1
- 229960004063 propylene glycol Drugs 0.000 abstract 1
- 235000013772 propylene glycol Nutrition 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 16
- YCMLQMDWSXFTIF-UHFFFAOYSA-N 2-methylbenzenesulfonimidic acid Chemical compound CC1=CC=CC=C1S(N)(=O)=O YCMLQMDWSXFTIF-UHFFFAOYSA-N 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 206010039491 Sarcoma Diseases 0.000 description 7
- 201000007270 liver cancer Diseases 0.000 description 6
- 241001529936 Murinae Species 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 3
- VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000037842 advanced-stage tumor Diseases 0.000 description 2
- 239000003005 anticarcinogenic agent Substances 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DCTOHCCUXLBQMS-UHFFFAOYSA-N 1-undecene Chemical compound CCCCCCCCCC=C DCTOHCCUXLBQMS-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- SENVVPJKUXKDKC-UHFFFAOYSA-N 4-aminobenzenesulfonamide;ethanol Chemical compound CCO.NC1=CC=C(S(N)(=O)=O)C=C1 SENVVPJKUXKDKC-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- JXASPPWQHFOWPL-UHFFFAOYSA-N Tamarixin Natural products C1=C(O)C(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 JXASPPWQHFOWPL-UHFFFAOYSA-N 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000007663 anodyne effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 201000010997 liver sarcoma Diseases 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-dimethylbenzene Natural products CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
实施例编号 | 聚乙二醇PEG-400 | 1,2-丙二醇 | 辛二酸 | 对甲苯磺酸 | 二甲基亚砜 | 乙醇 | 磺胺 |
4 | 10% | 5% | 1% | 1% | 3% | 0 | 对甲苯磺胺酰80% |
5 | 60% | 27% | 1% | 1% | 0 | 1% | 对甲苯磺酰胺10% |
6 | 15% | 10% | 20% | 20% | 20% | 5% | 邻甲苯磺酰胺10% |
7 | 20% | 15% | 10% | 5% | 5% | 5% | N-乙基对甲苯磺酰胺40% |
8 | 25% | 30% | 5% | 5% | 2% | 3% | N-乙基邻甲苯磺酰胺30% |
9 | 30% | 10% | 10% | 10% | 10% | 20% | N-环己基对甲苯磺酰胺10% |
10 | 20% | 20% | 5% | 15% | 20% | 0 | N-环己基邻甲苯磺酰胺20% |
11 | 药物改为对甲苯磺酰胺、邻甲苯磺酰胺、N-乙基对甲苯磺酰胺、N-乙基邻甲苯磺酰胺、N-环己基对甲苯磺酰胺、N-环己基邻甲苯磺酰胺各取等分。其余同实施例1。 | ||||||
12 | 药物改为N-环己基邻甲苯磺酰胺、N-环己基对甲苯磺酰胺,重量比2∶1,其余同实施例2。 | ||||||
13 | 药物改为N-乙基邻甲苯磺酰胺、N-环己基对甲苯磺酰胺,重量比2∶1,其余同实施例4。 |
批次 | 组别 剂量 动物数 体重 平均瘤重 抑瘤率 P值* |
(/kg/d×10d) 开始 最后 开始 最后 (x±SD)(g) (%) | |
1 | NS(对照) 2.0ml 11 11 21.5 27.8 3.05±0.93 -溶剂(对照) 2.0ml 11 11 21.9 26 0 2.56±0.70 16.1 >0 05*CTX 18.0mg 11 11 19.9 27.9 1.81±0.22 40.7 <0.01*实施例1 0.5ml 10 9 22.1 28.1 1 76±0.34 31.3 <0.01**实施例1 1.0m1 10 9 21.9 27.8 1.48±0.33 42.2 <0.01**实施例1 2.0ml 11 9 22.2 24.1 1.24±0.53 51.6 <0.01** |
2 | Ns(对照) 2.0ml 11 11 20.3 32.6 2.92±0.85 -溶剂(对照) 2.0ml 10 10 20.2 29.5 3.12±0.77 -6.8 >0.05*CTX 18.0mg 11 11 20.3 27.8 1.57±0.63 46.2 <1.01*实施例1 0.5ml 11 11 20.4 26.8 2.15±0.78 31.3 <0.01**实施例1 1.0m1 10 10 20.1 28.7 2.00±0.86 35.9 <0.01**实施例1 2.0ml 11 11 20.0 27.8 1.56±0.61 50.0 <0.01** |
3 | Ns(对照) 2.0ml 11 10 20 9 28.5 2.35±0.61 -溶剂(对照) 2.0ml 11 11 20.6 28.3 2.48±0.64 -5.5 >0.05*CTX 18.0mg 11 10 20.9 28.5 0.94±0.41 60.0 <0.01*实施例1 0.5ml 11 10 20.8 27 5 1.62±0.34 34.7 <0.01**实施例1 1.0ml 12 12 20.1 25.6 1.39±0.31 43.9 <0.01**实施例1 2.0m1 14 14 20.6 24.5 1.03±0.29 58.6 <0.01** |
批次 | 组别 剂量 动物数 体重 平均瘤重 抑瘤率 P值* |
(/kg/d×10d) 开始 最后 开始 最后 (X±SD)(g) (%) | |
4 | NS(对照) 2.0ml 11 11 22.5 30.3 2.83±0.97 -溶剂(对照) 2.0ml 11 11 22.4 27.1 3.36±0.69 -7.1 >0.05*CTX 18.0mg 11 11 22.4 30.9 1.37±0.47 51.6 <0.01*实施例1 0.5ml 11 10 22.0 29.1 1.64±0 68 45.9 <0.01**实施例1 1.0ml 11 10 22.4 27.5 1.76±0.44 41.9 <0.01**实施例1 2.0ml 11 9 22.4 27.3 1.04±0.62 65.7 <0.01** |
5 | NS(对照) 2.0ml 11 11 22.2 31.0 2.76±0.73 -溶剂(对照) 2.0ml 10 10 22.3 27.9 3.05±0.90 -10.5 >0.05*CTX 18.0mg 10 10 22.6 29.1 1.29±0.43 53.5 <0.01*实施例1 0.5ml 12 11 22.4 27.4 1.79±0.45 41.3 <0.01**实施例1 1.0ml 12 11 22.6 27.6 1.69±0.42 44.6 <0.01**实施例1 2.0ml 12 10 22.7 27.7 1.10±0.30 63.9 <0.01** |
6 | NS(对照) 2.0ml 11 11 19.1 27.8 2.40±0.73 -溶剂(对照) 2.0ml 12 11 19.4 26.2 2.33±0.40 2.9 >0.05*CTX 18.0mg 11 10 19.3 26.4 1.14±0.28 52.5 <0.01*实施例1 0.5ml 11 9 19.0 25.3 1.63±0.39 30.0 <0.01**实施例1 1.0ml 12 11 19.1 24.5 1.37±0.30 41.2 <0.01**实施例1 2.0ml 13 11 19.5 24.3 1.14±0.28 50.9 <0.01** |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN97108988A CN1073415C (zh) | 1997-07-03 | 1997-07-03 | 磺酰胺类化合物在制备抗癌药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN97108988A CN1073415C (zh) | 1997-07-03 | 1997-07-03 | 磺酰胺类化合物在制备抗癌药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1204511A CN1204511A (zh) | 1999-01-13 |
CN1073415C true CN1073415C (zh) | 2001-10-24 |
Family
ID=5170816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN97108988A Expired - Lifetime CN1073415C (zh) | 1997-07-03 | 1997-07-03 | 磺酰胺类化合物在制备抗癌药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1073415C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3243510A4 (en) * | 2015-01-06 | 2018-08-08 | Tianjin Hongri Jian Da Kang Medical Technology Co., Ltd | Sulfonamide pharmaceutical composition |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6727287B2 (en) | 2001-04-16 | 2004-04-27 | Pts International, Inc. | Toluene sulfonamide-containing anti-tumor composition and method of use thereof |
KR20050077916A (ko) * | 2004-01-29 | 2005-08-04 | 학교법인 성균관대학 | pH 및 온도 민감성 하이드로겔 |
CN102389410A (zh) * | 2011-11-03 | 2012-03-28 | 黄漫翔 | 对-甲苯磺酰胺在制备癌症治疗药物中的应用 |
US9668990B1 (en) * | 2016-06-10 | 2017-06-06 | Gongwin Biopharm Holdings Co., Ltd. | Benzenesulfonamides compositions for treatment of malignant pleural effusions |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3340148A (en) * | 1961-03-22 | 1967-09-05 | Gillette Inhibitor Co | Treatment of fungus diseases of the skin |
-
1997
- 1997-07-03 CN CN97108988A patent/CN1073415C/zh not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3340148A (en) * | 1961-03-22 | 1967-09-05 | Gillette Inhibitor Co | Treatment of fungus diseases of the skin |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3243510A4 (en) * | 2015-01-06 | 2018-08-08 | Tianjin Hongri Jian Da Kang Medical Technology Co., Ltd | Sulfonamide pharmaceutical composition |
RU2715700C2 (ru) * | 2015-01-06 | 2020-03-03 | Тяньцзинь Хунжи Цзянь Да Кан Медикал Текнолоджи Ко., Лтд | Сульфонамидная фармацевтическая композиция |
Also Published As
Publication number | Publication date |
---|---|
CN1204511A (zh) | 1999-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1222294C (zh) | 含吗啉蒽环类衍生物和抗癌剂的联合制剂 | |
CN1703223A (zh) | 喹唑啉衍生物 z d 6 4 7 4组合吉西他滨并任选组合电离辐射在治疗与血管生成和 /或血管通透性增加相关的疾病中的用途 | |
CN1224383C (zh) | 一类新型降低血糖化合物 | |
CN1073415C (zh) | 磺酰胺类化合物在制备抗癌药物中的应用 | |
CN1263466C (zh) | 活性炭输液剂、其制备方法及其在制备治疗癌症药中的应用 | |
CN101062041A (zh) | 葫芦素新的医药用途 | |
CN1217669C (zh) | 柚皮苷用于制备治疗咳嗽的药物 | |
CN1415630A (zh) | 银耳多糖,其制备方法和以该化合物为活性成分的药物组合物 | |
CN1468602A (zh) | 柚皮苷在制备支持性治疗非典型性肺炎药物中的应用 | |
CN102125558A (zh) | 一种复方左亚叶酸钠氟尿嘧啶抗肿瘤药 | |
CN1426783A (zh) | 吴茱萸碱在制药中的应用 | |
CN1080855A (zh) | 维生素矿物质防癌复方 | |
CN1504191A (zh) | 葫芦素脂质体组方及其制剂 | |
CN1056082C (zh) | 一种抗癌药 | |
RU2076710C1 (ru) | Лекарственное средство для лечения опухолевых заболеваний | |
CN1771909A (zh) | 一种青蒿素脂肪乳剂及其制备方法与应用 | |
CN1109545C (zh) | 螯合铁的制剂及其制备方法 | |
CN1546093A (zh) | 防治体虚感冒的药物及其制备方法 | |
WO2022121884A1 (zh) | 伊维菌素及其类似物在皮肤相关疾病治疗中的应用 | |
CN1313099C (zh) | 炭气凝胶输液剂、其制备方法及其应用 | |
CN1695716A (zh) | 治疗扁平疣的药膏及内服药 | |
RU2220717C2 (ru) | Препарат для лечения парвовирусного энтерита собак и способ его применения | |
CN1138556C (zh) | 一种治疗直结肠癌的药物组合物及其制备方法 | |
CN1199639C (zh) | 治疗亚急性甲状腺炎的药物 | |
CN1300592A (zh) | 通过tpa升高白细胞治疗肿瘤及静脉给药方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: GUO SHAOWEN WU CHONGHAN WU CHONGWEN Effective date: 20120530 Owner name: BEIJING JIANDAKANG NEW MEDICINE DEVELOPMENT CO., L Free format text: FORMER OWNER: WU YIZHUANG Effective date: 20120530 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510000 GUANGZHOU, GUANGDONG PROVINCE TO: 100020 CHAOYANG, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120530 Address after: 100020, room 1406, pan Li building, 22 Wai Wai Street, Beijing, Chaoyang District Patentee after: Beijing Jian Kang drug development Co. Ltd. Address before: Guangzhou City, Guangdong province 510000 City Changhua Street No. 12 2 floor Co-patentee before: Guo Shaowen Patentee before: Wu Yizhuang Co-patentee before: Wu Chonghan Co-patentee before: Wu Chongwen |
|
ASS | Succession or assignment of patent right |
Owner name: TIANJIN HONGRI JIANDAKANG PHARMACEUTICAL TECHNOLOG Free format text: FORMER OWNER: BEIJING JIANDAKANG NEW MEDICINE DEVELOPMENT CO., LTD. Effective date: 20120828 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100020 CHAOYANG, BEIJING TO: 300457 HANGU, TIANJIN |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120828 Address after: 300457 TEDA SME Park, 276 Huang Hai Road, Tianjin Development Zone, 4-C-203 Patentee after: TIANJIN HONGRI JIANDAKANG PHARMACEUTICAL CO., LTD. Address before: 100020, room 1406, pan Li building, 22 Wai Wai Street, Beijing, Chaoyang District Patentee before: Beijing Jian Kang drug development Co. Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20011024 |
|
CX01 | Expiry of patent term |